



Renal Involvement in COVID-19 Among Iranian Children

Masoumeh Mohkam ¹, Mahbube Mirzaee ^{1,*}, Fatemeh Abdollah Gorgi ², Sedigheh Rafiei Tabatabaei ³, Abdollah Karimi ³, Shahnaz Armin ³, Roxana Mansour Ghanaie ³, Seyed Alireza Fahimzad ³, Zahra Pournasiri ¹, Seyedohammadtaghi Hosseini Tabatabaei ¹, Nasrin Esfandiar ¹, Reza Dalirani ¹, Elham Pourbakhtyaran ⁴, Ayeh Yaraghi ⁴ and Fereshteh Karbasian ⁴

¹Pediatric Nephrology Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Mofid Children's Hospital, Tehran, Iran

³Pediatric Infections Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁴Department of Pediatric Emergency, Mofid Children's Hospital, Shahid Beheshti Medical University (SBMU), Tehran, Iran

*Corresponding author: Pediatric Nephrology Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: mahbube.mirzaee1368@gmail.com

Received 2020 July 20; Revised 2020 November 16; Accepted 2020 November 17.

Abstract

Background: Information about renal involvement in pediatric patients with COVID-19 is limited, and there is not enough data about renal and urinary tract involvement in children infected with this novel virus.

Objectives: This study aimed to determine the spectrum of kidney diseases in pediatric patients with COVID-19, admitted to a tertiary children's hospital.

Methods: This cross-sectional study was conducted on 71 pediatric patients with COVID-19 infection. Diagnosis of COVID-19 was established based on the guidelines by the Iranian Ministry of Health. The patients' demographic characteristics, clinical symptoms, laboratory results, and renal ultrasonography findings were extracted from the hospital medical records.

Results: On admission, 10% of patients had oliguria, 7.7% had edema, and 3% had hypertension. The first urinalysis indicated proteinuria, leukocyturia, and hematuria in 46%, 24%, and 23% of the patients, respectively. Overall, 40.7% of the patients showed some degree of renal involvement. During hospitalization, acute kidney injury (AKI) occurred in 34.5% of the patients. Based on the pediatric risk, injury, failure, loss of kidney function, and end-stage kidney disease (pRIFLE) classification, stage I (risk group) was found in 20% of patients, stage II (injury group) in 25% of patients, and stage III (failure group) in 55% of patients with AKI. The total mortality rate was estimated at 12.67%, and the incidence of in-hospital death was 30% in pediatric patients with severe COVID-19 infection associated with AKI.

Conclusions: The prevalence of AKI was high in patients with COVID-19 infection hospitalized in our tertiary hospital. We also found that a decrease in renal function was associated with a higher risk of mortality. Overall, early detection of AKI and effective treatment may help reduce mortality in patients with COVID-19.

Keywords: COVID-19, Child, AKI, Kidney Diseases, Mortality

1. Background

In December 2019, coronavirus disease 2019 (COVID-19) was first reported in Wuhan, China, and spread rapidly around the world (1). This pandemic was caused by a novel betacoronavirus, known as severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Its genome is partially similar to other coronaviruses, such as SARS-CoV and the Middle East respiratory syndrome-coronavirus (MERS-CoV). SARS-CoV-2 has a high reproductive number with a long incubation period and a lower fatality rate (significantly higher in high-risk patients with comorbidities) as compared to SARS-CoV and MERS-CoV (2).

The main features of COVID-19 include diffuse alveolar involvement and respiratory failure. Although renal involvement has not been reported as the first presentation of this disease, nephrologic problems occur, especially in patients admitted to the intensive care units (ICUs). Since the RNA of coronavirus has been detected in the plasma of 15% of patients by real-time-polymerase chain reaction (RT-PCR) (3), it seems that it can penetrate into other solid organs, such as the kidneys. In a previous report, hypoxic respiratory failure and oliguric renal failure after open surgery for aortic dissection were reported in a patient who died of COVID-19, and the pathological report revealed evidence of direct renal infection with SARS-CoV-2.

Also, electron microscopy of proximal tubules showed vacuolization, degenerated epithelial cells with multiple intracellular viral clusters, and intracytoplasmic viral arrays within tubular epithelial cells. This report suggested that direct infection of the renal tissue by SARS-CoV-2 occurs in the setting of AKI in COVID-19 patients (4).

In another study, acute kidney injury (AKI) was reported in 6.7% of patients infected with COVID-19, and the mortality rate of patients with AKI was 91.7% (5). Also, a study by Cheng indicated a mortality rate of 5.1% for AKI in patients with COVID-19, and indicators of renal involvement were associated with a higher risk of mortality. In this cohort, 16.1% of the patients expired at the hospital (6). Moreover, Zhao et al. (7) reported AKI in 5.5% of adult patients with COVID-19 (7). On the other hand, Wang et al. reported an increase in the serum creatinine level in 10.8% of patients, none of whom met the diagnostic criteria for AKI (8).

In the context of COVID-19, the results vary between adults and children. In a study by Lu and colleagues at Wuhan Children's Hospital among 1391 children, who were tested for COVID-19, only one ten-month-old infant died with multiple organ failure, whereas no major organ involvement was found in the rest of the patients (9). Overall, information about renal and urinary tract involvement in patients with COVID-19 is limited, and further investigations are needed. Also, patients with chronic renal diseases, and those who undergo dialysis are susceptible to this novel viral infection and its complications (10).

2. Objectives

There is not adequate information about renal and urinary tract involvement in children infected with COVID-19. Therefore, in this study, we aimed to determine the prevalence of renal and urinary tract disorders in pediatric patients with COVID-19 admitted to Mofid Children's Hospital, which is a referral hospital for pediatric patients with COVID-19 in Iran.

3. Methods

This cross-sectional study was conducted on 71 pediatric patients with COVID-19, admitted to the Tertiary Children's Hospital of Shahid Beheshti University of Medical Sciences in Tehran, Iran. All consecutive patients with a diagnosis of COVID-19, who were admitted to Mofid Children's Hospital from February 19 to April 19, 2020, were enrolled in this cohort study. Diagnosis of COVID-19 was established, according to the guidelines provided by the Iranian Ministry of Health. The diagnostic criteria, based on

the Iranian Expert's Consensus Statement, were as follows (11):

Clinical Data: Symptoms including fever, dry cough, and chills, or severe hypoxemia, acute hypercapnia, hemodynamic instability, and decreased level of consciousness in the absence of fever.

Laboratory Data: High levels of C-reactive protein (CRP), thrombocytopenia, or lymphocytopenia.

Imaging Data: Pulmonary involvement in favor of COVID-19 on chest X-ray (CXR) or computed tomography (CT) scan.

Positive results on high-throughput sequencing or RT-PCR.

According to the abovementioned criteria, the patients were divided into three groups, as follows (11):

Definite Cases: Children with a history, signs, and symptoms of COVID-19, together with abnormal chest CT scan results and positive PCR test results.

Suspected Cases: Children with a history, signs, and symptoms of COVID-19, abnormal chest CT scan results suggesting COVID-19 (if other causes of abnormal CT are ruled out), and negative PCR results.

Rejected Cases: Children with negative PCR results and abnormal chest CT scan due to causes, except COVID-19.

The patients' demographic characteristics, clinical symptoms (blood pressure, heart rate, respiratory rate, and body volume indices), laboratory data (complete blood count, urinalysis, liver function tests, blood urea nitrogen, first and serial serum creatinine levels, biochemical tests, erythrocyte sedimentation rate [ESR], CRP, and lactate dehydrogenase [LDH]), RT-PCR results for COVID-19, kidney ultrasonography, and medications were extracted from the electronic medical records. The glomerular filtration rate (GFR) was also calculated based on the Schwartz formula (12). Also, a normal serum creatinine level was considered as the local reference (0.5 to 1.0 mg/dL for children ages 3 to 18 years and 0.3 to 0.7 mg/dL for children younger than age 3) (13). AKI was also defined based on the pediatric risk, injury, failure, loss of kidney function, and end-stage kidney disease (pRIFLE) criteria (Table 1) (14).

The baseline serum creatinine level was defined as the initial serum creatinine level upon admission. Also, the onset time of AKI was defined as the earliest time of serum creatinine change meeting the RIFLE criteria.

The research protocol and informed consent were approved by the ethics committee of Pediatric Nephrology Research Center and Research Institute for Children's Health of Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Table 1. The pRIFLE Classification for AKI (14)

pRIFLE Stage	eCCL	Urine Output
R = Risk of renal dysfunction	decreased by 25%	< 0.5 mL/kg per hour for 8 hours
I = Injury to the kidney	decreased by 50%	< 0.5 mL/kg per hour for 16 hours
F = Failure of kidney function	decreased by 75%	< 0.3 mL/kg per hour for 24 hours or anuria for 12 hours
L = Loss of kidney function	Persistent failure > 4 weeks	
E = End-stage renal disease	Persistent failure > 3 months	

Abbreviation: eCCL, estimated creatinine clearance.

3.1. Statistical Analysis

Data were reported as mean \pm SD, and categorical variables were expressed as percentages. P-value less than 0.05 was considered statistically significant.

4. Results

A total of 71 pediatric patients with COVID-19 were included in this study. The result of COVID-19 PCR was positive in 40.9% of the patients. The rest of the children were diagnosed based on the criteria mentioned above. The mean age of the patients was 6.49 ± 5.07 years (range: 1 month-15 years), and 60% of them were male. Also, the mean weight of the patients was 23.4 ± 16.7 kg (range: 2.9 - 70 kg). The clinical features and laboratory data of the subjects are presented in Tables 2 and 3.

On admission, 10% of the patients had oliguria, 7.7% had edema, and 3% had hypertension. No patients showed signs of hypotension. The first urinalysis showed proteinuria, leukocyturia, and hematuria in 46%, 24%, and 23% of the patients, respectively. Overall, 40.7% of the patients showed some degree of renal involvement. During hospitalization, the peak serum creatinine level was 9.6 mg/dL (range: 0.4 - 9.6 mg/dL; mean: 1.3 ± 1 mg/dL), and the prevalence of AKI was 34.5%. Based on the pRIFLE classification, stage I (risk group) was found in 20% of the patients, stage II (injury group) in 25% of the patients, and stage III (failure group) in 55% of the patients with AKI.

Compared to patients with normal renal function, those with elevated serum creatinine levels on admission were predominantly older and more severely ill. The total mortality rate of the patients was 12.67%. The rate of in-hospital death among patients with AKI was estimated at 30%. The incidence of ICU admission and respiratory therapy in patients with elevated baseline serum creatinine levels was significantly higher than those with normal serum

Table 2. Clinical and Demographic Data of the Patients

	Mean \pm SD	Range
Age, y	6.49 ± 5.07	1 month-15 years
Weight, kg	23.47 ± 16.79	2.900 - 70
Systolic blood pressure, mmHg	97.39 ± 13.92	63 - 125
Diastolic blood pressure, mmHg	60.06 ± 11.64	31 - 76
Important clinical data, %		
Male patients	60	
Abnormal chest X-ray	77.8	
Abnormal chest CT scan	78.7	
Severe diseases	30	
Comorbidities	50	
ICU admission	35	
Mechanical ventilation	30	
Hydronephrosis	3.6	
Oliguria	10	
Edema	7.7	
AKI	34.5	
Stage I (risk group)	20 (of AKI group)	
Stage II (injury group)	25 (of AKI group)	
Stage III (failure group)	55 (of AKI group)	
Need for dialysis	0	
In-hospital death	12.67	

creatinine levels upon admission (35% vs. 16.1% and 30% vs. 15.6%, respectively). The final laboratory data showed mild abnormalities in the serum creatinine level of 30% of the patients, and the mean final level of serum creatinine was 0.83 ± 0.8 mg/dL (range: 0.3 - 4.8 mg/dL). The final urinalysis revealed leukocyturia in 12.5% of the patients, hematuria in 25% of the patients, and proteinuria in 33.3% of the patients.

5. Discussion

The results of this prospective study, which was conducted in a tertiary teaching hospital in Tehran, Iran, revealed the high prevalence of renal involvement in hospitalized pediatric patients with COVID-19. In this study, more than 40% of the patients showed evidence of renal involvement, with elevated serum creatinine levels in more than 34.5% of these patients. This is the first study examining the prevalence of renal and urinary tract involvement in pediatric patients with COVID-19 in Iran. The presence of renal involvement was associated with a higher in-hospital mortality rate. Compared to patients who did not

Table 3. The Laboratory Data of the Patients

	Mean \pm SD	Range
Leukocyte count, $\times 10^9/L$	9409.66 \pm 4701.65	2000 - 25,000
Lymphocytes, %	40.03 \pm 17.2	14 - 75
Platelet count, $\times 10^9/L$	248529.4 \pm 157790.2	60,000 - 793,000
Hemoglobin, g/dL	11.13 \pm 2.32	5.50 - 18.30
ESR, mm/h	43.66 \pm 11.05	31 - 60
CRP, mg/L	28.52 \pm 24	4 - 112
LDH, U/L	668.93 \pm 378.94	135 - 2300
Serum sodium, mEq/L	137.06 \pm 4.19	130 - 155
Serum potassium, mEq/L	4.13 \pm 0.61	2.90 - 5.80
Serum calcium, mg/dL	8.4 \pm 1.26	4.1 - 10.1
Serum phosphate, mg/dL	4.24 \pm 1.43	2 - 8
Serum magnesium, mg/dL	2.12 \pm 0.24	1.7 - 2.9
PCO ₂ , mmHg	29.85 \pm 20.17	20 - 87
Serum bicarbonate, mEq/L	17.70 \pm 12.49	3 - 47
Blood urea nitrogen, mg/dL	15.08 \pm 10	9 - 90
Serum creatinine, mg/dL	1.30 \pm 1.	0.4 - 9.6

develop AKI after admission, the patients who developed AKI had a more severe disease and even showed failure of other organs, besides a higher in-hospital mortality rate. In comparison, patients with acute renal failure were more likely to be admitted to pediatric ICUs. They were also more likely to be managed with vasopressors for hypotension, have multiple organ failure, and receive ventilation therapy during hospitalization.

In this regard, Cheng et al. (6) assessed the relationship between markers of renal insufficiency and death in patients with COVID-19 in a cohort study of 701 individuals in December 2019 in Wuhan, Hubei Province, China. The results showed that 16.1% of the patients expired at the hospital. On admission, proteinuria was detected in 43.9% of the patients, hematuria in 26.7% of the patients, and increased serum creatinine levels in 14.4% of the patients. The rate of AKI among patients was 5.1% during admission. Patients with elevated baseline levels of serum creatinine showed a significantly higher incidence of AKI as compared to patients with a normal baseline serum creatinine (11.9% vs. 4.0%) (6).

On the other hand, the involvement of multiple organs, including the liver, kidneys, urinary tract, and gastrointestinal tract, has been reported in COVID-19 patients (4). In a study by Zhao et al. (7), comorbidities, including kidney disease, hypertension, chronic lung disease, malignancies, and diabetes, were more common in the severe disease group (40% vs. 14.8%; $P = 0.009$). They also reported

acute pulmonary, renal, and cardiovascular involvement in the patients, and the rate of AKI was 5.5% in this report (15). Surprisingly, in New York City, USA, the rate of AKI was estimated at 36%, according to the kidney disease: Improving global outcomes (KDIGO) definition, 14.3% of whom required renal replacement therapy (RRT). Also, most of the AKI cases (89.7%) and 96.8% of the patients who required RRT were on mechanical ventilation. In this report, a mortality rate of 35% was measured in patients with AKI (16). Overall, AKI is strongly associated with increased mortality and morbidity rates in severely ill patients (17-19).

We found that patients with AKI were more likely to be admitted to ICUs and receive respiratory support; therefore, renal involvement represented a higher risk of deterioration in these patients. In our study, indicators of renal involvement at admission and the increased level of creatinine were associated with a higher risk of mortality. Therefore, monitoring of renal function and urinalysis must be emphasized, even in patients with mild symptoms. Also, attention must be paid to altered kidney function test results and electrolyte imbalances after the hospitalization of pediatric patients with COVID-19. Early detection of renal failure and timely management, involving appropriate hydration, adequate hemodynamic, electrolyte, and acid base support, and improved protection of the kidneys with avoidance of nephrotoxic drugs, may help improve the prognosis of these patients.

The etiology of nephrologic problems in patients with COVID-19 is likely to be multifactorial. This novel virus may exert direct effects on the renal tissues of infected patients (3). Recently, it has been reported that angiotensin converting enzyme 2 (ACE2) is a cell entry receptor for COVID-19 (20). In this regard, Li et al. (21) in a human study revealed that ACE2 expression in the renal tissue was nearly 100 folds higher than in the lungs. Accordingly, renal involvement may be caused by coronavirus through an ACE2-dependent pathway.

Another etiological factor for renal involvement in COVID-19 is the deposition of immune complexes, such as viral antigens and antibodies or virus-specific T-cell lymphocytes or antibodies in the kidney cells. Besides, infection-induced cytokines may have indirect effects on the renal tissue and other organs due to hypoxia, hypoxemia, and shock. Further research is needed to determine the potential kidney pathophysiology in patients with COVID-19. The first reports clarified that COVID-19 infection and mortality are rare in the pediatric population. However, recent clinical and epidemiological evidence shows that no particular age group is immune to this viral infection. Renal involvement is frequent in severe pediatric cases and usually presents as AKI in the context of multiple organ failure, caused by direct viral invasion or

acute inflammatory responses (22).

Pediatric patients with COVID-19 are susceptible to AKI, which can increase the mortality rate. On the other hand, pediatric patients with chronic kidney diseases and other chronic disorders are susceptible to severe COVID-19, which can increase the total rate of mortality in this group. In children, COVID-19 may be less severe as compared to adults (23, 24). In this regard, Bush et al. (25) reported the case of a 13-year-old male from USA, who acquired COVID-19 infection five years post-kidney transplantation, with excellent clinical outcomes in a very short-term follow-up. Also, Melgosa et al. (26) reported 16 pediatric patients with chronic renal involvement who were diagnosed with COVID-19 in Spain. The severity of symptoms was mild in most patients with limited radiological findings (26).

Moreover, according to a study by Robertson et al. (27), there are additional reports of neonatal, maternal, and under-five mortality, resulting from disruptions in the delivery and utilization of health services and decreased access to food. Therefore, pediatricians need to be aware of the risks of these problems and should carefully evaluate all pediatric patients with chronic diseases in outpatient clinics for early detection of COVID-19 and prevention of multiple organ failure, resulting in death. It is certain that timely supportive therapy and accurate patient control are useful methods for the management of this group of patients (28).

The present study has several limitations. First, we did not have access to the baseline laboratory data, and the baseline BUN and serum creatinine levels of many patients were not available, which might have led to the misdiagnosis or underestimation of AKI. Second, although we tried to adjust for many confounders, other unknown confounders might have played a role. Third, because of the outbreak, the clinical and paraclinical data of our patients were not available after discharge; therefore, we could not demonstrate the effects of the virus on the outcomes and long-term complications. Therefore, further investigations are required to determine the precise effect of this virus on long-term kidney function and the prevalence of CKD in pediatric patients. In future studies, we aim to follow-up these patients for several months and will report the long-term renal complications of COVID-19 in these children.

5.1. Conclusions

The prevalence of AKI in pediatric patients infected with COVID-19 was high in our tertiary hospital. The presence of AKI in hospitalized pediatric patients was associated with an increased risk of mortality. Therefore, pediatricians should be aware of renal involvement in patients

with COVID-19 infection. Also, early detection of renal involvement, based on the clinical and paraclinical parameters, besides effective management, may help reduce the mortality rate of patients with COVID-19.

Acknowledgments

We greatly appreciate the COVID-19 ward staff of Mofid Children's Hospital for their efforts in treating the patients during this outbreak.

Footnotes

Authors' Contribution: Masoumeh Mohkam and Mahbube Mirzaee developed the original concept and protocol of the study, designed the study, collected the data, and wrote the manuscript. Fatemeh Abdollah Gorgi designed the statistical tests and analyzed the data. Zahra Pournasir, Seyedohammadtaghi Hosseini Tabatabaei, Nasrin Esfandiar, and Reza Dalirani contributed to writing the manuscript. Sedigheh Rafiei Tabatabaei, Abdollah Karimi, Shahnaz Armin, Roxana Mansour Ghanaie, and Seyed Alireza Fahimzad collected the data, conceived the project, and supervised and coordinated the study.

Conflict of Interests: All authors declare no competing interests.

Ethical Approval: This research has been approved by Pediatric nephrology research center proposal code 99-05.

Funding/Support: The authors received no financial support for the research, authorship, and/or publication of this article.

References

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. 2020;**382**(13):1199–207. doi: [10.1056/NEJMoa2001316](https://doi.org/10.1056/NEJMoa2001316). [PubMed: [31995857](https://pubmed.ncbi.nlm.nih.gov/31995857/)]. [PubMed Central: [PMC7121484](https://pubmed.ncbi.nlm.nih.gov/PMC7121484/)].
2. Xie M, Chen Q. Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV. *Int J Infect Dis*. 2020;**94**:119–24. doi: [10.1016/j.ijid.2020.03.071](https://doi.org/10.1016/j.ijid.2020.03.071). [PubMed: [32247050](https://pubmed.ncbi.nlm.nih.gov/32247050/)]. [PubMed Central: [PMC7118633](https://pubmed.ncbi.nlm.nih.gov/PMC7118633/)].
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;**395**(10223):497–506. doi: [10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
4. Farkash EA, Wilson AM, Jentzen JM. Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2. *J Am Soc Nephrol*. 2020;**31**(8):1683–7. doi: [10.1681/ASN.2020040432](https://doi.org/10.1681/ASN.2020040432). [PubMed: [32371536](https://pubmed.ncbi.nlm.nih.gov/32371536/)]. [PubMed Central: [PMC7460898](https://pubmed.ncbi.nlm.nih.gov/PMC7460898/)].
5. Chu KH, Tsang WK, Tang CS, Lam MF, Lai FM, To KF, et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. *Kidney Int*. 2005;**67**(2):698–705. doi: [10.1111/j.1523-1755.2005.67130.x](https://doi.org/10.1111/j.1523-1755.2005.67130.x). [PubMed: [15673319](https://pubmed.ncbi.nlm.nih.gov/15673319/)]. [PubMed Central: [PMC7112337](https://pubmed.ncbi.nlm.nih.gov/PMC7112337/)].

6. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int.* 2020;**97**(5):829–38. doi: [10.1016/j.kint.2020.03.005](https://doi.org/10.1016/j.kint.2020.03.005). [PubMed: [32247631](https://pubmed.ncbi.nlm.nih.gov/32247631/)]. [PubMed Central: [PMC7110296](https://pubmed.ncbi.nlm.nih.gov/PMC7110296/)].
7. Zhao XY, Xu XX, Yin HS, Hu QM, Xiong T, Tang YY, et al. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. *BMC Infect Dis.* 2020;**20**(1):311. doi: [10.1186/s12879-020-05010-w](https://doi.org/10.1186/s12879-020-05010-w). [PubMed: [32345226](https://pubmed.ncbi.nlm.nih.gov/32345226/)]. [PubMed Central: [PMC7188494](https://pubmed.ncbi.nlm.nih.gov/PMC7188494/)].
8. Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China. *Am J Nephrol.* 2020;**51**(5):343–8. doi: [10.1159/000507471](https://doi.org/10.1159/000507471). [PubMed: [32229732](https://pubmed.ncbi.nlm.nih.gov/32229732/)]. [PubMed Central: [PMC7179524](https://pubmed.ncbi.nlm.nih.gov/PMC7179524/)].
9. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. *N Engl J Med.* 2020;**382**(17):1663–5. doi: [10.1056/NEJMc2005073](https://doi.org/10.1056/NEJMc2005073). [PubMed: [32187458](https://pubmed.ncbi.nlm.nih.gov/32187458/)]. [PubMed Central: [PMC7121177](https://pubmed.ncbi.nlm.nih.gov/PMC7121177/)].
10. Mohkam M, Kompani F. Prevention of the Emerging COVID-19 Infection in Dialysis Centers. *J Pediatr Nephrol.* 2020;**8**(2).
11. Karimi A, Rafiei Tabatabaei S, Rajabnejad M, Pourmoghaddas Z, Rahimi H, Armin S, et al. An Algorithmic Approach to Diagnosis and Treatment of Coronavirus Disease 2019 (COVID-19) in Children: Iranian Expert's Consensus Statement. *Arch Pediatr Infect Dis.* 2020;**8**(2). doi: [10.5812/pedinf.102400](https://doi.org/10.5812/pedinf.102400).
12. Fadem SZ. *Kidney Foundation K/DOQI Guidelines*. CKiD Schwartz Equation; 2020. Available from: <http://www.kidney.org/doqi/kdoqi/toc.htm>.
13. Shams S, Kadkhodaei M, Alipour M. The reference range evaluation for creatinin among children under 8 in Tehran citizens. *Tehran Univ Med J.* 2000;**58**(1):92–6.
14. Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in critically ill children with acute kidney injury. *Kidney Int.* 2007;**71**(10):1028–35. doi: [10.1038/sj.ki.5002231](https://doi.org/10.1038/sj.ki.5002231). [PubMed: [17396113](https://pubmed.ncbi.nlm.nih.gov/17396113/)].
15. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature.* 2020;**579**(7798):270–3. doi: [10.1038/s41586-020-2012-7](https://doi.org/10.1038/s41586-020-2012-7). [PubMed: [32015507](https://pubmed.ncbi.nlm.nih.gov/32015507/)]. [PubMed Central: [PMC7095418](https://pubmed.ncbi.nlm.nih.gov/PMC7095418/)].
16. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. *Kidney Int.* 2020;**98**(1):209–18. doi: [10.1016/j.kint.2020.05.006](https://doi.org/10.1016/j.kint.2020.05.006). [PubMed: [32416116](https://pubmed.ncbi.nlm.nih.gov/32416116/)]. [PubMed Central: [PMC7229463](https://pubmed.ncbi.nlm.nih.gov/PMC7229463/)].
17. Imani PD, Odiit A, Hingorani SR, Weiss NS, Eddy AA. Acute kidney injury and its association with in-hospital mortality among children with acute infections. *Pediatr Nephrol.* 2013;**28**(11):2199–206. doi: [10.1007/s00467-013-2544-2](https://doi.org/10.1007/s00467-013-2544-2). [PubMed: [23872929](https://pubmed.ncbi.nlm.nih.gov/23872929/)].
18. Sutherland SM, Byrnes JJ, Kothari M, Longhurst CA, Dutta S, Garcia P, et al. AKI in hospitalized children: comparing the pRIFLE, AKIN, and KDIGO definitions. *Clin J Am Soc Nephrol.* 2015;**10**(4):554–61. doi: [10.2215/CJN.01900214](https://doi.org/10.2215/CJN.01900214). [PubMed: [25649155](https://pubmed.ncbi.nlm.nih.gov/25649155/)]. [PubMed Central: [PMC4386245](https://pubmed.ncbi.nlm.nih.gov/PMC4386245/)].
19. Mohkam M, Kompani F, Afjei A, Golchin F, Gorji FA. RIFLE Criteria in Critically Ill Neonates with Acute Kidney Injury. *J Pediatr Nephrol.* 2015;**3**(1):16–21.
20. Patel AB, Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? *JAMA.* 2020;**323**(18):1769–70. doi: [10.1001/jama.2020.4812](https://doi.org/10.1001/jama.2020.4812). [PubMed: [32208485](https://pubmed.ncbi.nlm.nih.gov/32208485/)].
21. Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. Caution on kidney dysfunctions of 2019-nCoV patients 202. *Med Rxiv Preprint.* 2020. doi: [10.1101/2020.02.08.20021212](https://doi.org/10.1101/2020.02.08.20021212).
22. Emad Momtaz H. Renal involvement in children with COVID-19 infection. *J Renal Inj Prev.* 2020;**9**(3):e20. doi: [10.34172/jrip.2020.20](https://doi.org/10.34172/jrip.2020.20).
23. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among Children in China. *Pediatrics.* 2020;**145**(6). doi: [10.1542/peds.2020-0702](https://doi.org/10.1542/peds.2020-0702). [PubMed: [32179660](https://pubmed.ncbi.nlm.nih.gov/32179660/)].
24. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. *JAMA.* 2020;**323**(13):1313–4. doi: [10.1001/jama.2020.2131](https://doi.org/10.1001/jama.2020.2131). [PubMed: [32058570](https://pubmed.ncbi.nlm.nih.gov/32058570/)]. [PubMed Central: [PMC7042807](https://pubmed.ncbi.nlm.nih.gov/PMC7042807/)].
25. Bush R, Johns F, Acharya R, Upadhyay K. Mild COVID-19 in a pediatric renal transplant recipient. *Am J Transplant.* 2020;**20**(10):2942–5. doi: [10.1111/ajt.16003](https://doi.org/10.1111/ajt.16003). [PubMed: [32406181](https://pubmed.ncbi.nlm.nih.gov/32406181/)]. [PubMed Central: [PMC7272978](https://pubmed.ncbi.nlm.nih.gov/PMC7272978/)].
26. Melgosa M, Madrid A, Alvarez O, Lumbreras J, Nieto F, Parada E, et al. SARS-CoV-2 infection in Spanish children with chronic kidney pathologies. *Pediatr Nephrol.* 2020;**35**(8):1521–4. doi: [10.1007/s00467-020-04597-1](https://doi.org/10.1007/s00467-020-04597-1). [PubMed: [32435879](https://pubmed.ncbi.nlm.nih.gov/32435879/)]. [PubMed Central: [PMC7237873](https://pubmed.ncbi.nlm.nih.gov/PMC7237873/)].
27. Robertson T, Carter ED, Chou VB, Stegmuller AR, Jackson BD, Tam Y, et al. Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study. *Lancet Global Health.* 2020;**8**(7):e901–8. doi: [10.1016/s2214-109x\(20\)30229-1](https://doi.org/10.1016/s2214-109x(20)30229-1).
28. Esfandiar N, Kompani F. Fluid Therapy in COVID-19 Disease. *J Pediatr Nephrol.* 2020;**8**(2).